Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Key Takeaway: Merck and Gilead have provided an update on the Phase 3 KEYNOTE-D46/EVOKE-03 study. However, the article lacks specific details regarding the findings or implications of this update. Further information may be necessary to understand the impact of this study on the biopharma landscape.